<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211206053291N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-02-20</date_registration>
      <primary_sponsor>Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran</primary_sponsor>
      <public_title>lidocaine effect on extubation</public_title>
      <acronym></acronym>
      <scientific_title>The effect of intravenous lidocaine on reducing the complications of endotracheal intubation after cardiac surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-01-08</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61127</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Randomization is performed using permuted balanced block (block of four) method. In order to observe concealment and blinding at the same time, the random sequence will be converted into composite codes (not group names) and these codes will be provided to the main researcher in closed envelopes. There is no difference in appearance, volume and type of syringe between the two groups of drugs and placebo
During the study, after opening each envelope, a syringe corresponding to that code is given to the patient, Blinding description: Extubating the pt when the patient is calm and breathing slowly with a spontaneous ventilator mode 1.5 mg / weight of 2% intravenous lidocaine is injected intravenously (1.5 cc / weight of syringe containing lidocaine at a dose of 1.5 ml / cc).In the control group, 1.5 cc of normal serum will be injected intravenously in terms of weight at the same time under the same conditions.Syringes containing lidocaine or normal saline will be exactly the same and will be coded by a third party And delivered to the head of the nursing shift randomly based on the number of patients who have the conditions of study and then injected by them to the patient at a specified time.Heart rate, blood pressure and possible arrhythmia are assessed before and during the injection, 5 minutes after the injection, and finally one minute after the endotracheal tube is removed and 10 minutes after it, and are completed in a special form by the patient's responsible nurse.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Larangospasm..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 45 patients who have weaning and extubation conditions for at least 6 to 12 hours after surgery. For this purpose, the patient should have relatively simple heart surgery involving vascular occlusion (CABG) or only single valve surgery. Also dangerous arrhythmia and instability. Cardiac (patients treated with epinephrine or Levofed at doses above 1.1 / macro / kg) and respiratory (po2≤60mmhg or (pco2≥50) are also excluded from our study Our study enters. Intervention 2: Control group: For 45 patients, 1.5 cc/kg of normal intravenous saline will be injected at the same time under the same conditions. Syringes containing lidocaine or normal saline will be exactly the same and will be coded by a third person to the nursing shift randomly based on the number of patients The study is delivered and then injected by the patient at a specific time.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Abdolreza Dayani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Valiasr ave,shahid rajaei cardivascular hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1995614331</zip>
        <telephone>+98 21 2266 3250</telephone>
        <email>dr.a.dayani@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Abdolreza Dayani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Valiasr ave,shahid rajaei cardivascular hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1995614331</zip>
        <telephone>+98 21 2266 3250</telephone>
        <email>dr.a.dayani@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>simple cardiac surgury(CABG or valvular)
No history of smoking and drug or alcohol addiction during the last 10 years before surgery
No history of any drug or food allergies
All patients took beta-blockers around the operation and in the morning
No history of lung problems (asthma, COPD, etc.) treated with oral or inhaled drugs</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>85 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Dangerous arrhythmia during or after surgery
Hemodynamic instability including: cardiac instability (patients treated with epinephrine or levofed at doses above 1.1 μg / kg) and respiratory instability (po2≤60mmhg or pco2≥50) during postoperative time
Bleeding so much that the patient becomes a candidate for reoperation
Injection of lidocaine for any reason after surgery
EF drop after surgery
Use of ECMO or pump balloons after surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J95.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Postprocedural subglottic stenosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 45 patients who have weaning and extubation conditions for at least 6 to 12 hours after surgery. For this purpose, the patient should have relatively simple heart surgery involving vascular occlusion (CABG) or only single valve surgery. Also dangerous arrhythmia and instability. Cardiac (patients treated with epinephrine or Levofed at doses above 1.1 / macro / kg) and respiratory (po2≤60mmhg or (pco2≥50) are also excluded from our study Our study enters</i_keyword>
      <i_keyword>Control group: For 45 patients, 1.5 cc/kg of normal intravenous saline will be injected at the same time under the same conditions. Syringes containing lidocaine or normal saline will be exactly the same and will be coded by a third person to the nursing shift randomly based on the number of patients The study is delivered and then injected by the patient at a specific time</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cough occurs after extubation. Timepoint: The onset of cough is assessed before and during injection, 5 minutes after injection, and finally one minute after endotracheal tube removal and 10 minutes after. Method of measurement: The incidence of cough is measured by three criteria of cough, which include: 1- no cough or temporary cough following the exit of the endotracheal tube, 2- incidence of cough by breathing, and 3- persistent cough without respiratory stimulation when the endotracheal tube exits up to 10 minutes later. The questionnaire is mentioned.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-12-04</approval_date>
        <contact_name>Research Ethics Committees of Rajaie Cardiovascular Medical and Research Center</contact_name>
        <contact_address>valiasr st,niyayesh highway,shahid rajaei cardiovascular center tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
